Cyril Amarchand Mangaldas Advised The Book Running Lead Managers On Anthem Biosciences Limited’s IPO

Cyril Amarchand Mangaldas advised JM Financial, Citigroup, J.P. Morgan, and Nomura on Anthem Biosciences Limited’s ₹33,950 million IPO, which was oversubscribed 63.86 times.

Update: 2025-07-23 07:30 GMT


Cyril Amarchand Mangaldas advised the book running lead managers on Anthem Biosciences Limited’s IPO

Cyril Amarchand Mangaldas advised the book running lead managers — JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, and Nomura Financial Advisory and Securities (India) Private Limited — in connection with the initial public offering (IPO) of Anthem Biosciences Limited.

Anthem is an innovation-driven and technology-focused contract research, development and manufacturing organization (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing. The IPO was a pure offer for sale of equity shares by certain existing shareholders, aggregating to ₹33,950 million. The equity shares were listed on the stock exchanges on July 21, 2025, with the issue oversubscribed 63.86 times, delivering a premium of 26.85% over the issue price of ₹570.

The Cyril Amarchand Mangaldas deal team was led by Reuben Chacko (Partner & Regional Co-Head – Capital Markets – South) and Vartika Jain (Partner), with assistance from Bhaskar Kumar (Associate), Dhruv Sharma (Associate), Prakhar Jain (Associate), Joe George (Associate), and Rakshitha V (Associate).

Click to know more about Cyril Amarchand Mangaldas

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 88796 34922.

Tags:    

Similar News